Time to onset of adverse events

Phase 2/3 Trials in Xydalba clinical trial programme

Graph showing that the distribution of day of onset of adverse events in patients receiving XYDALBA was similar to that on the comparator regimens

The distribution of day of onset of adverse events in patients receiving Xydalba was similar to that on the comparator regimens11.

11 Dunne MW et al. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Drug Safety. 2015